drugset / Trial / NCT03480672

Postoperative aRCH With Cisplatin Versus aRCH With Cisplatin and Pembrolizumab in Locally Advanced Head and Neck Squamous Cell Carcinoma

NCT03480672 ↗

Phase 2 Completed 211 enrolled University of Leipzig
RandomizedParallel-groupOpen-labelTreatment

Summary

This trial evaluates the addition of pembrolizumab to standard postoperative adjuvant radiochemotherapy in the treatment of patients with locally advanced intermediate and high risk head and neck squamous cell carcinoma (HNSCC).

Timeline

Start
2018-08-06
Primary completion
2025-01-30
Completion
2025-01-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Pembrolizumab Monoclonal antibody 200 mg Intravenous